Brief: Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
25/03/2025 11:36
March 25 (Reuters) - Quoin Pharmaceuticals Ltd 2EBy.BE: QUOIN PHARMACEUTICALS FILES U.S. PATENT APPLICATION FOR NOVEL TOPICAL FORMULATIONS TO TREAT NETHERTON SYNDROME AND OTHER SKIN DISEASES QUOIN PHARMACEUTICALS LTD - IF GRANTED, PATENT WOULD PROVIDE PROTECTION FOR QRX003 UNTIL 2045 Source text: ID:nGNX5Gq0KD Further company coverage: [2EBy.BE] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quoin Pharmaceuticals
See all newsQuoin Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview
Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview
NASDAQ RESUMED AT 10:15 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:06 AM